STOCK TITAN

Compass Therapeutics Inc - CMPX STOCK NEWS

Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.

About Compass Therapeutics Inc.

Compass Therapeutics Inc. (Nasdaq: CMPX) is a clinical-stage oncology-focused biopharmaceutical company dedicated to developing innovative antibody-based therapeutics to treat a range of cancers and other human diseases. Headquartered in Boston, Massachusetts, Compass leverages cutting-edge science to address the intricate relationship between angiogenesis, the immune system, and tumor growth. The company’s mission is to deliver transformative therapies that target critical biological pathways, enabling more effective anti-tumor responses.

Core Focus and Proprietary Platforms

Compass Therapeutics is at the forefront of antibody discovery and development, with a focus on bispecific antibodies, monoclonal antibodies, and engineered protein constructs. The company’s proprietary platforms, including StitchMabs and common light chain technologies, empower researchers to empirically identify optimal drug combinations. This approach allows for rapid translation of preclinical insights into tailored therapeutics with monoclonal-like manufacturability, positioning Compass as a leader in the field of combinatorial immunotherapy.

Pipeline and Clinical Programs

Compass Therapeutics boasts a robust pipeline targeting multiple critical pathways involved in tumor progression and immune evasion:

  • Tovecimig (CTX-009): A bispecific antibody targeting DLL4 and VEGF-A, designed to inhibit angiogenesis and tumor vascularization. Currently in Phase 2/3 clinical trials for advanced biliary tract cancers (BTC) and being evaluated for additional indications like colorectal cancer (CRC).
  • CTX-471: A novel CD137 agonist antibody that activates immune effector cells within the tumor microenvironment. Early clinical results suggest potential efficacy in melanoma, small-cell lung cancer, and mesothelioma, with biomarker-driven Phase 2 trials planned.
  • CTX-8371: A next-generation bispecific checkpoint inhibitor targeting PD-1 and PD-L1, with a unique mechanism involving proteolytic cleavage of cell surface PD-1. This program is in Phase 1 trials for solid tumors.
  • CTX-10726: A newly announced PD-1 x VEGF-A bispecific antibody advancing through preclinical development, with an IND submission expected by year-end 2025.

These candidates reflect Compass’s commitment to addressing high unmet medical needs, particularly in patient populations resistant to existing therapies.

Scientific Excellence and Biomarker-Driven Strategy

Compass Therapeutics integrates biomarker-driven strategies into its clinical development programs. For example, the identification of NCAM (CD56) as a potential biomarker for CTX-471 highlights the company’s ability to leverage cutting-edge science to enhance patient selection and therapeutic efficacy. Similarly, the use of DLL4 as a biomarker in CRC studies underscores Compass’s precision medicine approach.

Collaborative and Industrialized Approach

The company’s “partnership-first” mentality enables it to collaborate with top-tier academic institutions and leverage best-in-class technologies. This decentralized validation model accelerates the transition from discovery to clinical development, ensuring that only the most promising therapeutic combinations advance to human trials.

Competitive Landscape and Market Position

Operating in the highly competitive field of oncology-focused biopharmaceuticals, Compass Therapeutics distinguishes itself through its emphasis on bispecific antibodies and its robust biomarker-driven approach. Competitors include established players like Genentech and Bristol Myers Squibb, but Compass’s focus on immune-oncology and angiogenesis modulation positions it uniquely within the market. The company’s ability to identify and exploit novel biological pathways gives it a competitive edge in addressing complex cancer mechanisms.

Challenges and Opportunities

While Compass Therapeutics faces challenges typical of clinical-stage biopharma companies—such as regulatory hurdles and the inherent risks of drug development—it is well-positioned to overcome these obstacles through its innovative platforms, strong clinical pipeline, and strategic collaborations. The growing emphasis on immuno-oncology and biomarker-driven therapies provides significant opportunities for the company to expand its impact and market presence.

Conclusion

Compass Therapeutics Inc. exemplifies innovation and scientific rigor in the biopharmaceutical industry. With a robust pipeline, proprietary technologies, and a focus on addressing unmet medical needs, the company is poised to make significant contributions to the field of oncology. By targeting critical pathways involved in tumor growth and immune modulation, Compass is advancing the next generation of cancer therapeutics, offering hope to patients worldwide.

Rhea-AI Summary
Compass Therapeutics receives FDA Fast Track Designation for CTX-009 in combination with Paclitaxel for treating metastatic or locally advanced Biliary Tract Tumors. The bispecific antibody has shown promising clinical responses in Phase 2 study. Top-line data for COMPANION-002 study expected by end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
-
Rhea-AI Summary
Compass Therapeutics, Inc. (CMPX) announces poster presentations on CTX-009, a bispecific antibody, at the Cholangiocarcinoma Foundation 2024 Annual Conference. The presentations focus on patient selection hypotheses using real-world data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
Rhea-AI Summary
Compass Therapeutics, Inc. (CMPX) will participate in the Stifel Targeted Oncology Days virtually on April 16-17, 2024, presenting their antibody-based therapeutics for various human diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
conferences
-
Rhea-AI Summary
Compass Therapeutics, Inc. provided an update on their clinical trials for CTX-009, CTX-471, and CTX-8371, reporting progress in enrollment and potential biomarkers. Financially, the company ended 2023 with $152 million in cash and marketable securities, extending their cash runway into mid-2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
-
Rhea-AI Summary
Compass Therapeutics, Inc. (CMPX) will participate in the Leerink Partners Global Biopharma Conference on March 13, 2024, to showcase its antibody-based therapeutics for human diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
conferences
Rhea-AI Summary
Compass Therapeutics, Inc. (Nasdaq: CMPX) announces the publication of a peer-reviewed article on CTX-8371, a bispecific checkpoint inhibitor showing enhanced anti-tumor activity. The data revealed a unique mechanism-of-action targeting PD-1 and PD-L1, leading to increased efficacy in experimental models. The combination with CTX-471 further improved anti-tumor effects, indicating promising potential for proprietary combination therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
-
Rhea-AI Summary
Compass Therapeutics, Inc. (CMPX) reported a business update, including progress in clinical trials for CTX-009 in biliary tract and colorectal cancer, positive clinical activity in the Phase 1b study of CTX-471, and FDA acceptance of the CTX-8371 IND. The company also announced a CEO succession plan and ended 2023 with an estimated $152 million in cash and marketable securities, providing cash runway into mid-year 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.16%
Tags
none
-
Rhea-AI Summary
Compass Therapeutics, Inc. (CMPX) reports Q3 and year-to-date 2023 financial results, opened 29 clinical sites for COMPANION-002 and continues to enroll patients in the U.S. Phase 2/3 study of CTX-009 in combination with Paclitaxel for advanced biliary tract cancers. Received IND clearance for CTX-8371, a next generation bispecific checkpoint inhibitor, and announces a CEO succession plan. Ended Q3 with $164 million in cash and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
Rhea-AI Summary
Compass Therapeutics, Inc. (Nasdaq: CMPX) will participate in investor events at the Stifel Healthcare Conference in New York on November 14, 2023, and the Jefferies London Healthcare Conference on November 16, 2023. The presentations will be available for replay for 90 days on Compass' Events page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What is the current stock price of Compass Therapeutics (CMPX)?

The current stock price of Compass Therapeutics (CMPX) is $2.24 as of April 1, 2025.

What is the market cap of Compass Therapeutics (CMPX)?

The market cap of Compass Therapeutics (CMPX) is approximately 304.2M.

What does Compass Therapeutics Inc. specialize in?

Compass Therapeutics focuses on developing antibody-based therapeutics to target cancer and immune pathways, leveraging proprietary platforms like StitchMabs.

What are Compass Therapeutics’ key pipeline products?

Key products include Tovecimig (CTX-009), CTX-471, CTX-8371, and CTX-10726, targeting pathways like DLL4, VEGF-A, PD-1, PD-L1, and CD137.

How does Compass Therapeutics differentiate itself in the oncology market?

Compass stands out with its focus on bispecific antibodies, biomarker-driven strategies, and its proprietary platforms for rapid therapeutic development.

What is the significance of biomarkers in Compass’s clinical programs?

Biomarkers like NCAM and DLL4 guide patient selection and enhance therapeutic efficacy, ensuring precision in clinical development.

What challenges does Compass Therapeutics face?

Challenges include regulatory hurdles, clinical trial risks, and competition in the oncology-focused biopharma sector.

What is the company’s approach to collaboration?

Compass adopts a partnership-first mentality, working with top-tier academic institutions and leveraging best-in-class technologies.

What are the clinical applications of Tovecimig (CTX-009)?

Tovecimig is being developed for advanced biliary tract cancers and colorectal cancer, targeting DLL4 and VEGF-A pathways.

What is CTX-471, and how does it work?

CTX-471 is a CD137 agonist antibody that activates immune effector cells in the tumor microenvironment, showing promise in melanoma and other cancers.
Compass Therapeutics Inc

Nasdaq:CMPX

CMPX Rankings

CMPX Stock Data

304.22M
89.46M
18.08%
70.94%
2.67%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
BOSTON